Brief: Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
30/01/2026 17:30
Jan 30 (Reuters) - Elevar Therapeutics: ELEVAR THERAPEUTICS: ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR RIVOCERANIB IN COMBINATION WITH CAMRELIZUMAB ELEVAR THERAPEUTICS: FDA ASSIGNED PDUFA TARGET ACTION DATE OF JULY 23, 2026 Source text: ID:nGNXNlP5s Further company coverage: 028300.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLB
See all newsBrief: Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
Brief: Elevar Therapeutics Resubmits NDA To U.S. FDA For Camrelizumab Plus Rivoceranib Astreatment For Unresectable Hepatocellular Carcinoma
Brief: Hlb Inc To Acquire 16 Billion Won Worth Of Shares In Neurotobe Pharmaceuticals Inc
Health Rounds: Exercise helps with sexual dysfunction after prostate cancer treatment
Brief: HLB Inc Signs 18.5 Billion Won Supply Deal